Clinical Trial Update: Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the effect of recombinant factor VIIa on perioperative blood loss in patients undergoing major burn surgery; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burns

Drugs mentioned

• NovoSeven RT (Recombinant activated factor VII)

Snippet

Sponsor: United States Army Institute of Surgical Research | Conditions: Burns | Phase 3 | Status: COMPLETED | Results posted: 2013-03-06